Xilio Therapeutics Inc

Change company Symbol lookup

Select an option...

XLO Xilio Therapeutics Inc

PHT Pioneer High Income Fund, Inc.

BTAL AGFiQ U.S. Market Neutral Anti-Beta Fund

BIGC Bigcommerce Holdings Inc

OP Oceanpal Inc

AMZN Amazon.com Inc

BHR Braemar Hotels & Resorts Inc

X United States Steel Corp

ELV Elevance Health Inc

SREA Sempra Energy

Go

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.